Statements (64)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
biotechnology company
|
| gptkbp:acquisition |
Vaxart,_Inc._acquired_by_a_private_equity_firm
|
| gptkbp:businessModel |
strategic partnerships
biotech startup |
| gptkbp:CEO |
gptkb:W._Scott_Hutton
|
| gptkbp:clinicalTrials |
gptkb:United_States
gptkb:COVID-19_vaccine ongoing regulatory compliance Phase 1 Phase 2 randomized controlled trials private investors multiple phases planned healthy volunteers data analysis ongoing preliminary results published targeted populations |
| gptkbp:collaborations |
gptkb:National_Institutes_of_Health
|
| gptkbp:communityPartnerships |
academic institutions
|
| gptkbp:deathDate |
gptkb:VXA-VP1
|
| gptkbp:employeeCount |
50-100
|
| gptkbp:focus |
oral vaccines
|
| gptkbp:founded |
2007
|
| gptkbp:funding |
venture capital
|
| gptkbp:hasPrograms |
experts in immunology
|
| gptkbp:hasResearchInterest |
vaccine market analysis
|
| gptkbp:headquarters |
gptkb:South_San_Francisco,_California
|
| gptkbp:historicalResearch |
international research initiatives
immunological studies |
| https://www.w3.org/2000/01/rdf-schema#label |
Vaxart, Inc.
|
| gptkbp:investmentFocus |
institutional investors
publicly traded company quarterly earnings calls |
| gptkbp:market |
global vaccine market
|
| gptkbp:marketSegment |
focus on oral vaccines
|
| gptkbp:notable_player |
oral route
ongoing research under investigation new vaccine technologies focused on oral delivery systems global distribution plans recombinant viral vector vaccine |
| gptkbp:partnerships |
gptkb:AstraZeneca
biopharmaceutical companies |
| gptkbp:patentCitation |
multiple patents in vaccine technology
|
| gptkbp:productLine |
multiple vaccine candidates
|
| gptkbp:products |
VXA-CoV2-1
|
| gptkbp:publications |
scientific journals
|
| gptkbp:regulatoryCompliance |
FDA_approval_process
FDA_submissions |
| gptkbp:reignStart |
various viral infections
|
| gptkbp:reproduction |
oral tablet form
|
| gptkbp:research |
government grants
|
| gptkbp:researchFocus |
infectious diseases
|
| gptkbp:researchInterest |
global health organizations
|
| gptkbp:stockSymbol |
gptkb:VXRT
|
| gptkbp:technology |
proprietary technology
VAAST_platform |
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:updates |
press releases
|
| gptkbp:wasAffecting |
contract manufacturing partners
safety assessments conducted |
| gptkbp:website |
www.vaxart.com
|